The FDA has removed its hold on clinical trials of Dynavax’s hepatitis B vaccine candidate HEPLISLAV which have been stopped for a year and a half following one patient in a trial being diagnosed with a rare disease that causes inflammation of the blood vessels. HEPLISLAV is being designed to provide better protection in two doses rather than the current vaccine’s three dose system. The company plans to start trials in patients with chronic kidney disease.
저작권자 © 메디칼업저버 무단전재 및 재배포 금지